Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by T Saito
Total Records ( 2 ) for T Saito
  T Satoh , I Okamoto , M Miyazaki , R Morinaga , A Tsuya , Y Hasegawa , M Terashima , S Ueda , M Fukuoka , Y Ariyoshi , T Saito , N Masuda , H Watanabe , T Taguchi , T Kakihara , Y Aoyama , Y Hashimoto and K. Nakagawa
 

Purpose: YM155, a novel molecular targeted agent, suppresses survivin, a member of the inhibitor of apoptosis protein family that is overexpressed in many tumor types. The aim of this study was to determine the maximum tolerated dose (MTD) and to assess the safety, pharmacokinetics, and antitumor activity of YM155 in patients with advanced refractory solid tumors.

Experimental Design: Patients with advanced refractory solid tumors were treated with escalating doses of YM155 administered by continuous i.v. infusion for 168 hours in 21-day cycles.

Results: Of the 34 patients enrolled, 33 (median age, 59 years) received at least 1 dose of YM155 (range, 1-19 cycles). The dose levels studied were 1.8, 3.6, 4.8, 6.0, 8.0, and 10.6 mg/m2/d. The MTD was determined to be 8.0 mg/m2/d, based on a dose-limiting toxicity of increased blood creatinine observed in 2 patients receiving 10.6 mg/m2/d. The most common adverse reactions judged to be related to YM155 were urine microalbumin present; fever; injection-site phlebitis; fatigue; and decreased hemoglobin/anemia, blood albumin, and lymphocyte count. The pharmacokinetic profile was almost linear over the dosing range and was similar between cycles 1 and 2. Urinary excretion of YM155 showed no definite difference among doses. Stable disease was achieved in nine patients.

Conclusions: YM155 was safely administered to patients with advanced refractory solid tumors by 168-hour continuous i.v. infusion in 21-day cycles. The MTD was determined to be 8.0 mg/m2/d. The safety profile, plasma concentrations achieved, and antitumor activity observed merit further studies with this survivin suppressant, alone and in combination regimens.

  T Yuasa , M Iijima , S Ito , T Muguruma , T Saito and I. Mizoguchi
 

The effects of 2 years of storage and 6000 thermocycles on the shear bond strength (SBS) of two self-etching adhesive systems were studied. Two self-etching primer (SEP) systems (Transbond Plus and Beauty Ortho Bond) and one etch and rinse system (Transbond XT) were used to bond brackets to 126 human premolars that were then stored in artificial saliva for 24 hours or 2 years and thermocycled in distilled water before SBS testing with a universal testing machine. The adhesive remnant index (ARI) scores were calculated. Data were compared by two-way analysis of variance and chi-square analysis. Enamel/adhesive interfaces were examined by scanning electron microscopy.

There was no significant difference in the mean SBS for the bonding materials among the three conditions. ARI scores showed that Transbond XT and Beauty Ortho Bond had less adhesive remaining on the teeth after ageing compared with storage for 24 hours. Specimens bonded with Beauty Ortho Bond showed leakage between the resin adhesive and enamel after ageing. Both SEP systems produced adequate SBS even after 2 years or 6000 times thermocycling. Thermocycling is an appropriate technique for determining the durability of orthodontic bracket bonding materials.

 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility